Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about a user seeking advice on adding GHK-Cu to RU58841 for hair loss treatment, while already using oral minoxidil, dutasteride, ketoconazole shampoo, and considering LLLT. They are unsure about the concentration and carrier solution for GHK-Cu.

GHK-Cu is discussed for its potential anti-aging and healing properties, with some users considering its effects on hair growth. One user mentions using Folligen Spray and topical finasteride, noting improved healing but uncertain hair growth results.

Using vitamin C in shampoo to adjust pH levels can improve hair health and reduce oiliness and dandruff. The user mixed vitamin C powder with conditioner, achieving positive results.

The conversation is about purchasing RU58841 for hair loss treatment from Xian Lyphar BioTech. Users confirm the company is legitimate and the price is reasonable.

The conversation discusses the use of RU58841 for hair loss, with one user sharing a one-month difference in their hair after using it. Users discuss where to buy RU58841, potential side effects including heart issues, and mixed opinions on its effectiveness, with some questioning the need for treatment based on the before and after pictures.

The conversation is about the effectiveness of Fluridil (Eucapil) for hair loss compared to RU58841, with the original poster considering Fluridil a safer and potentially more effective alternative.

A monoclonal antibody clinical trial for potential hair loss treatments in Victoria, Australia and the discussion of their efficacy. People shared information about similar drugs already on the market, speculated about potential side effects, and discussed how to spread the word about the trial.

The conversation is about hair loss treatments, specifically discussing RU58841, with concerns about its safety and lack of research. Alternatives like finasteride, dutasteride, and minoxidil are mentioned, with some users sharing personal experiences and side effects.

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.

Low Dose Naltrexone (LDN) may reduce inflammation in alopecia conditions. It is discussed as a potential adjunct treatment with finasteride or dutasteride for androgenic alopecia.

The conversation discusses the best carrier for RU58841, comparing Ethanol and PEG400. The user seeks advice on which carrier is more effective.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

A user experienced hair loss and texture changes, tried minoxidil and finasteride, and considered antihistamines like Cetirizine for potential histamine issues. They reported improved alertness but continued shedding.

The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.

Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.

The conversation discusses sourcing pyrilutamide from China for hair loss treatment, highlighting its potency compared to other AR antagonists like bicalutamide and RU58841. The user expresses interest in trying pyrilutamide despite mixed results in clinical trials.

A user inquired about purchasing KX-826 for hair loss if approved in China. Another user provided links to purchase it without waiting for U.S. approval.

Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

The user experienced side effects from RU58841, including dry eyes and potential eyesight issues, and decided to stop using it. They confirmed the product's legitimacy but advised caution due to its experimental status and lack of safety data.

KPV, a peptide patented by L'Oreal, may promote hair growth and reduce hair loss by extending the anagen phase and has anti-inflammatory properties. It could be combined with treatments like minoxidil for enhanced effects.

A user reported hair regrowth and increased thickness after 11 months using finasteride 1mg, taken 3-4 times a week, with noticeable improvement starting around the third or fourth month. No side effects were mentioned, and the user is considering reducing the dosage to find the minimum needed to maintain results.

The user is seeking advice on a hair loss treatment called Ell Cranell, which contains Alfatradiol. Another user shared information from a study stating that Alfatradiol only slows down or stabilizes hair loss, but does not increase hair density or thickness.

The Shiseido/Replicel RCH-01 trial results were disappointing and ineffective. Users expressed skepticism and frustration, suggesting alternatives like Tsuji or simply accepting baldness.

KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

The conversation discusses a hair loss treatment regimen including oral dutasteride, oral minoxidil, tadalafil, and the recent addition of RU58841. The user shares experiences with these treatments, noting significant hair regrowth and stabilization, and discusses the cost and preparation of RU58841.

Ecklonia cava is suggested as an alternative to finasteride and dutasteride for hair growth, potentially offering benefits without their side effects. It is promoted for anti-aging, mood enhancement, and cognitive support.

Celery juice is discussed as a potential treatment for crown balding, with skepticism from users. The conversation highlights differences between alopecia areata and male pattern baldness.